ERK signaling mediates long-term low concentration 3,3'-diindolylmethane inhibited nasopharyngeal carcinoma growth and metastasis: An in vitro and in vivo study

Li,Fen; Chen,Chen; Chen,Shi-Ming; Xiao,Bo-Kui; Tao,Ze-Zhang

doi:10.3892/or.2015.4428

ERK signaling mediates long-term low concentration 3,3'-diindolylmethane inhibited nasopharyngeal carcinoma growth and metastasis: An in vitro and in vivo study

Authors:
- Fen Li
- Chen Chen
- Shi-Ming Chen
- Bo-Kui Xiao
- Ze-Zhang Tao
View Affiliations

Affiliations: Otolaryngology-Head and Neck Surgery Research Institute, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: November 16, 2015 https://doi.org/10.3892/or.2015.4428
Pages: 955-961

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It is well known that crucifers have antitumor effects and 3,3'-diindolylmethane (DIM) is one of the major bioactive components, and the associated molecular mechanisms in a short-term high-dose manner are widely discussed. However, the antitumor effects of DIM in a long-term low-dose manner in nasopharyngeal carcinoma (NPC) has not been reported yet, as to the potential mechanisms in the human body. In the present study, NPC cells were induced by 20 µmol/l DIM for over a month, and the proliferation, apoptosis, migration and in vivo metastasis were investigated. The results showed that DIM significantly reduced the proliferation and migration; however, changes in apoptosis were not observed. In vivo study showed the metastasis was significantly reduced. Compared to the short-term high-dose manner, incomplete similar qualities were observed; next we explored the possible signal pathway revolved, the ERK signaling showed similar changes, while the PI3K/Akt, NF-κB, P38, JNK pathways were significantly altered in the short-term high-dose manner (our previous study) showed no obvious change, indicating the ERK signaling may be the main effector of DIM.

View Figures

View References

1	Safe S, Papineni S and Chintharlapalli S: Cancer chemotherapy with indole-3-carbinol, bis(3′-indolyl)methane and synthetic analogs. Cancer Lett. 269:326–338. 2008. View Article : Google Scholar : PubMed/NCBI
2	Chinnakannu K, Chen D, Li Y, Wang Z, Dou QP, Reddy GP and Sarkar FH: Cell cycle-dependent effects of 3,3′-diindolyl-methane on proliferation and apoptosis of prostate cancer cells. J Cell Physiol. 219:94–99. 2009. View Article : Google Scholar
3	Jin Y, Zou X and Feng X: 3,3′-Diindolylmethane negatively regulates Cdc25A and induces a G2/M arrest by modulation of microRNA 21 in human breast cancer cells. Anticancer Drugs. 21:814–822. 2010. View Article : Google Scholar : PubMed/NCBI
4	Wang YQ, Chen C, Chen Z, Xu Y, Wang Y, Xiao BK, Chen SM and Tao ZZ: Indole-3-carbinol inhibits cell proliferation and induces apoptosis in Hep-2 laryngeal cancer cells. Oncol Rep. 30:227–233. 2013.PubMed/NCBI
5	Ahmad A, Kong D, Wang Z, Sarkar SH, Banerjee S and Sarkar FH: Down-regulation of uPA and uPAR by 3,3′-diin-dolylmethane contributes to the inhibition of cell growth and migration of breast cancer cells. J Cell Biochem. 108:916–925. 2009. View Article : Google Scholar : PubMed/NCBI
6	Kim EJ, Shin M, Park H, Hong JE, Shin HK, Kim J, Kwon DY and Park JH: Oral administration of 3,3′-diindolylmethane inhibits lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice. J Nutr. 139:2373–2379. 2009. View Article : Google Scholar : PubMed/NCBI
7	Ali S, Banerjee S, Ahmad A, El-Rayes BF, Philip PA and Sarkar FH: Apoptosis-inducing effect of erlotinib is potentiated by 3,3′-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer. Mol Cancer Ther. 7:1708–1719. 2008. View Article : Google Scholar : PubMed/NCBI
8	Banerjee S, Wang Z, Kong D and Sarkar FH: 3,3′-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer Res. 69:5592–5600. 2009. View Article : Google Scholar : PubMed/NCBI
9	Rahman KMW, Banerjee S, Ali S, Ahmad A, Wang Z, Kong D and Sakr WA: 3,3′-Diindolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation. Cancer Res. 69:4468–4475. 2009. View Article : Google Scholar : PubMed/NCBI
10	Smith S, Sepkovic D, Bradlow HL and Auborn KJ: 3,3′-Diindolyl-methane and genistein decrease the adverse effects of estrogen in LNCaP and PC-3 prostate cancer cells. J Nutr. 138:2379–2385. 2008. View Article : Google Scholar : PubMed/NCBI
11	Vivar OI, Lin CL, Firestone GL and Bjeldanes LF: 3,3′-Diindolyl-methane induces a G₁ arrest in human prostate cancer cells irrespective of androgen receptor and p53 status. Biochem Pharmacol. 78:469–476. 2009. View Article : Google Scholar : PubMed/NCBI
12	Hsu EL, Chen N, Westbrook A, Wang F, Zhang R, Taylor RT and Hankinson O: CXCR4 and CXCL12 down-regulation: A novel mechanism for the chemoprotection of 3,3′-diindolylmethane for breast and ovarian cancers. Cancer Lett. 265:113–123. 2008. View Article : Google Scholar : PubMed/NCBI
13	Rajoria S, Suriano R, George A, Shanmugam A, Schantz SP, Geliebter J and Tiwari RK: Estrogen induced metastatic modulators MMP-2 and MMP-9 are targets of 3,3′-diindolylmethane in thyroid cancer. PLoS One. 6:e158792011. View Article : Google Scholar
14	Chen C, Chen SM, Xu B, Chen Z, Wang F, Ren J, Xu Y, Wang Y, Xiao BK and Tao ZZ: In vivo and in vitro study on the role of 3,3′-diindolylmethane in treatment and prevention of nasopharyngeal carcinoma. Carcinogenesis. 34:1815–1821. 2013. View Article : Google Scholar : PubMed/NCBI
15	Manach C, Williamson G, Morand C, Scalbert A and Rémésy C: Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr. 81(Suppl 1): 230S–242S. 2005.PubMed/NCBI
16	Howells LM, Moiseeva EP, Neal CP, Foreman BE, Andreadi CK, Sun YY, Hudson EA and Manson MM: Predicting the physiological relevance of in vitro cancer preventive activities of phytochemicals. Acta Pharmacol Sin. 28:1274–1304. 2007. View Article : Google Scholar : PubMed/NCBI
17	Cho HJ, Park SY, Kim EJ, Kim JK and Park JH: 3,3′-Diindolyl-methane inhibits prostate cancer development in the transgenic adenocarcinoma mouse prostate model. Mol Carcinog. 50:100–112. 2011. View Article : Google Scholar : PubMed/NCBI
18	Heath EI, Heilbrun LK, Li J, Vaishampayan U, Harper F, Pemberton P and Sarkar FH: A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3′- Diindolylmethane) in castrate-resistant, non-metastatic prostate cancer. Am J Transl Res. 2:402–411. 2010.PubMed/NCBI
19	Moiseeva EP, Almeida GM, Jones GDD and Manson MM: Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells. Mol Cancer Ther. 6:3071–3079. 2007. View Article : Google Scholar : PubMed/NCBI
20	Koon HK, Chan PS, Wong RNS, Wu ZG, Lung ML, Chang CK and Mak NK: Targeted inhibition of the EGFR pathways enhances Zn-BC-AM PDT-induced apoptosis in well-differentiated nasopharyngeal carcinoma cells. J Cell Biochem. 108:1356–1363. 2009. View Article : Google Scholar : PubMed/NCBI
21	Horikawa T, Yoshizaki T, Kondo S, Furukawa M, Kaizaki Y and Pagano JS: Epstein-Barr Virus latent membrane protein 1 induces Snail and epithelial-mesenchymal transition in metastatic nasopharyngeal carcinoma. Br J Cancer. 104:1160–1167. 2011. View Article : Google Scholar : PubMed/NCBI
22	Qu C, Liang Z, Huang J, Zhao R, Su C, Wang S, Wang X, Zhang R, Lee MH and Yang H: MiR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTEN. Cell Cycle. 11:785–796. 2012. View Article : Google Scholar : PubMed/NCBI
23	Wong VC, Chen H, Ko JM, Chan KW, Chan YP, Law S, Chua D, Kwong DL, Lung HL, Srivastava G, et al: Tumor suppressor dual-specificity phosphatase 6 (DUSP6) impairs cell invasion and epithelial-mesenchymal transition (EMT)-associated phenotype. Int J Cancer. 130:83–95. 2012. View Article : Google Scholar
24	Yang F, Qian XJ, Qin W, Deng R, Wu XQ, Qin J, Feng GK and Zhu XF: Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma. PLoS. 8:e598792013. View Article : Google Scholar
25	Xie YQ, Wu XB and Tang SQ: Curcumin treatment alters ERK-1/2 signaling in vitro and inhibits nasopharyngeal carcinoma proliferation in mouse xenografts. Int J Clin Exp Med. 7:108–114. 2014.PubMed/NCBI
26	Chen LC, Liu HP, Li HP, Hsueh C, Yu JS, Liang CL and Chang YS: Thymidine phosphorylase mRNA stability and protein levels are increased through ERK-mediated cytoplasmic accumulation of hnRNP K in nasopharyngeal carcinoma cells. Oncogene. 28:1904–1915. 2009. View Article : Google Scholar : PubMed/NCBI
27	Peng C, Liu HY, Zhou M, Zhang LM, Li XL, Shen SR and Li GY: BRD7 suppresses the growth of nasopharyngeal carcinoma cells (HNE1) through negatively regulating beta-catenin and ERK pathways. Mol Cell Biochem. 303:141–149. 2007. View Article : Google Scholar : PubMed/NCBI